← Back to Clinical Trials
Recruiting NCT04162444

NCT04162444 Results of the Aortic Valve Reconstruction in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04162444
Status Recruiting
Phase
Sponsor National Medical Research Center for Children's Health, Russian Federation
Condition Aortic Valve Insufficiency
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2020-02-18
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 29 Days
Max Age 12 Years
Study Type OBSERVATIONAL
Interventions
Physical examinationThe Ross Classification for Heart Failure in ChildrenThe Aristotle score

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2020-02-18 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aortic valve disease counts up to 5% of cases of congenital heart disease being one of the most common congenital malformations of the cardiovascular system. This disease requires replacement of the damaged valve which in itself is not a trivial task to complete in children as there is still no available best practice for valve replacement. Today, the following alternative variants are performed in children: mechanical aortic prosthesis, xenografts, allografts, and pulmonary autograft (Ross procedure) and each has its potential advantages and disadvantages. Mechanical aortic prostheses require lifelong anticoagulation therapy and repeated surgeries to replace mechanical valves during child growth. Available xenografts in children also has suboptimal results not only because of absence of growth potential, but also due to development of degenerative changes in biological tissue of the graft leaflets. Allograft tissues are exposed to rapid biodegradation in the recipient body and thus requiring repeated surgeries associated with higher difficulty, high risk of hemorrhages, and injury of the coronary injuries. Ross procedure was proposed as theoretically the most evidence-based reconstruction of the aortic valve in children. Even successfully performed Ross operation transforms one-valve disorder into two-valve disease. The accumulation of knowledge on the anatomy of the aortic root and improvement of surgical techniques led to the development of new methods for reconstruction of the valve function. The technique is widely applied in adult cardiac surgery, uses glutaraldehyde-treated autopericardium for augmentation of the leaflets. Absence of foreign material provides no need for anticoagulation therapy. Potentially, reconstruction of the aortic valve with autopericardium can be widely used in children. Aim is to study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease. Patients aged 29 days to 12 years will be included into the study. The data according to the protocol of the study will be assessed at the stage of inclusion, during the surgery, in 30 days after the surgery, and in 1, 2, and 3 years after the surgery. Data about all the patients included into the research will be analyzed in order to study the endpoints and achieve the research aim.

Eligibility Criteria

Inclusion Criteria: * Age from 29 days to 12 years * Patient's official caregivers have to sign the informed consent after they are thoroughly explained the meaning of the study, its protocol and timelines. * Patients with manifestations, with mean gradient at the aortic valve \>40 mmHg with normal left ventricular ejection fraction (LVEF), or patients with manifestations with the mean gradient \< 40 mmHg with decreased LVEF, or patients with manifestations with severe aortic insufficiency, or patients without manifestations, but with decreased LVEF with aortic insufficiency, or patients with concomitant moderate aortic insufficiency and moderate aortic stenosis with manifestations. * Aortic Z-score over -1,5 * Absence of subvalvular and supravalvular aortic stenosis * Absence of intracardiac malformations requiring correction, except for septal defects Non-inclusion criteria: * Known hypersensitivity to aspirin, heparin, nitinol, intravenous contrast or contradictions to their administration due to other causes. * Previous replacement of the aortic valve with mechanical or xenografts. * Confirmed active sepsis or endocarditis. * Hypoplasia of the fibrous ring of the aortic valve with Z score under -1,5. * Life expectancy less than 3 years due to concomitant diseases. * Participation in another clinical research. * Indications for urgent surgery. * Intracardiac malformations requiring momentary surgical correction. * Geographical instability of a patient and his/her official caregivers, complicating significantly the constant contact during the study Exclusion Criteria: • Refusal of patient's caregivers to participate further in the study.

Contact & Investigator

Central Contact

Vladimir P. Miroshnichenko, PhD

✉ miroshnichenko@nczd.ru

📞 +7 499 134-04-70

Principal Investigator

Dmitry V. Ryabtsev, PhD

PRINCIPAL INVESTIGATOR

National Research Center of Children's Health

Frequently Asked Questions

Who can join the NCT04162444 clinical trial?

This trial is open to participants of all sexes, aged 29 Days or older, up to 12 Years, studying Aortic Valve Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04162444 currently recruiting?

Yes, NCT04162444 is actively recruiting participants. Contact the research team at miroshnichenko@nczd.ru for enrollment information.

Where is the NCT04162444 trial being conducted?

This trial is being conducted at Moscow, Russia.

Who is sponsoring the NCT04162444 clinical trial?

NCT04162444 is sponsored by National Medical Research Center for Children's Health, Russian Federation. The principal investigator is Dmitry V. Ryabtsev, PhD at National Research Center of Children's Health. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology